Shared on22 Oct 25
Analysts have raised their average price target for Harrow, citing increased confidence in the company's commercial execution and long-term revenue growth potential. Recent updates reflect new targets up to $74, compared to previous levels between $42 and $70.
Shared on08 Oct 25Fair value Increased 10%
Harrow's analyst price target has increased from $61.98 to $68.18. Analysts point to a stronger revenue growth outlook and heightened optimism regarding the company's commercial execution and product pipeline.
Shared on24 Sep 25Fair value Increased 3.12%
Analysts have raised Harrow's price target to $61.98, reflecting optimism about upcoming biosimilar launches, a strengthening market position in eye care, and expectations for upside to current revenue guidance. Analyst Commentary Introduction of ophthalmic biosimilars Byooviz and Opuviz expected to materially contribute to revenue starting in 2026.